CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR–refractory large B-cell lymphoma

The prognosis of patients with large B-cell lymphoma (LBCL) that progresses after treatment with chimeric antigen receptor (CAR) T-cell therapy targeting CD19 (CAR19) is poor. We report on the first 3 consecutive patients with autologous CAR19-refractory LBCL who were treated with a single infusion...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Blood
Hoofdauteurs: Baird, John H., Frank, Matthew J., Craig, Juliana, Patel, Shabnum, Spiegel, Jay Y., Sahaf, Bita, Oak, Jean S., Younes, Sheren F., Ozawa, Michael G., Yang, Eric, Natkunam, Yasodha, Tamaresis, John, Ehlinger, Zachary, Reynolds, Warren D., Arai, Sally, Johnston, Laura, Lowsky, Robert, Meyer, Everett, Negrin, Robert S., Rezvani, Andrew R., Shiraz, Parveen, Sidana, Surbhi, Weng, Wen-Kai, Davis, Kara L., Ramakrishna, Sneha, Schultz, Liora, Mullins, Chelsea, Jacob, Allison, Kirsch, Ilan, Feldman, Steven A., Mackall, Crystal L., Miklos, David B., Muffly, Lori
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society of Hematology 2021
Onderwerpen:
Clinical Trials and Observations
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8085484/
https://ncbi.nlm.nih.gov/pubmed/33512414
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020009432
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items